

EYE Financial Report for year ended 30 June 2026

Highlights

- Full year sales of A\$34.9 million up 26% in constant currency on the prior year
- EBITDA positive of A\$0.2 million in the six months to 30 June 2026
- Full year EBITDA loss of A\$2.0 million an improvement of A\$3.5 million on the prior year
- Audited A\$ financial statements in line with the unaudited US\$ financial information provided on 29 July 2026

Guidance for FY27 reaffirmed

- FY27 sales, excluding China, expected to be between US\$26 million and US\$31 million (A\$38 million to A\$45 million at AUD1.00 = USD0.69), implying growth of 15% to 37% on FY26 in US\$
- The Company expects to generate a positive EBITDA in FY27
- Cash on hand and existing, yet unused (at the date of this release), debt facility (total A\$3.75 million) are expected to be sufficient to meet working capital requirements and stated guidance growth targets

Nova Eye Medical Limited (ASX: EYE) (**Nova Eye Medical** or **the Company**), a medical technology company committed to advanced treatment technologies and devices in the global interventional glaucoma market, is pleased to provide its audited financial statements in Australian dollars for the year ended 30 June 2026.

Revenue, gross margin and operating costs from the audited financial statements are summarised in the table below:

	FY25 A\$ millions	H1FY26 A\$ millions	H2FY26 A\$ millions	FY26 A\$ millions
Revenue ⁽¹⁾	29.3	16.7	18.2	34.9
Gross Margin	20.1	11.7	13.3	25.0
Gross Margin %	69%	70%	73%	72%
Sales and marketing	(16.8)	(9.4)	(10.2)	(19.6)
Clinical data investment	(1.0)	(0.9)	(0.5)	(1.4)
Operations ⁽²⁾	(5.0)	(2.7)	(2.2)	(4.9)
Product development and engineering ⁽²⁾	(3.2)	(1.1)	(1.1)	(2.2)
Net corporate costs and other income ⁽¹⁾	(1.7)	(0.9)	(0.2)	(1.1)
Total Operating Expenditure	(27.7)	(15.0)	(14.2)	(29.2)
EBIT (loss)	(7.6)	(3.3)	(0.9)	(4.2)
Depreciation and amortisation ⁽²⁾	2.1	1.1	1.1	2.2
EBITDA/(Loss)	(5.5)	(2.2)	0.2	(2.0)

1) Grant income and freight recoveries included as “other income” in audited financial statements.

2) Operations costs includes A\$ 1.0 million (FY25 A\$1.0 million) of depreciation of PPE. Product Development and Engineering includes A\$ 1.2 million (FY25 \$1.1 million) of amortisation of intangibles

Gross margin improved due to increased sales in direct markets (USA and Germany) and declining manufacturing costs (driven by both scale and process improvements). This was augmented by an improvement in the operating expenditure-to-sales ratio, driven by continued sales growth, high-impact marketing, sales force productivity, and a reduction in costs and grant income associated with 2RT.

The business has now reached a scale where EBITDA is expected to continue to improve.

FY27 Guidance Reaffirmed

In the USA, we estimate that between 30,000 and 35,000 glaucoma surgical procedures per month are carried out on patients with mild to moderate glaucoma. Surgeries with the Company’s iTrack™ technology account for approximately 3% to 5% of those procedures, and therefore, there continues to be scope to grow in the USA.

Nearly two months into the new financial year, the Company continues to believe that the growth outlook is strong and confirms the following guidance for the 12 months ending 30 June 2027:

- Sales, excluding China, are expected to be between US\$26 million and US\$31 million (A\$38 million to A\$45 million at AUD1.00 = USD0.69)
- The Company expects to generate a positive EBITDA
- Cash on hand and existing, yet unused (at the date of this release), debt facility (total liquidity A\$3.75 million) are expected to be sufficient to meet working capital requirements and stated guidance growth targets

-END-

Authorised for lodgement by the Board of Directors of Nova Eye Medical Limited.

For more information please contact:

Company

Tom Spurling
Managing Director
+61 417 818 658

tspurling@nova-eye.com

Investors

Mark Flynn
Investor Relations
+61 416 068 733

mflynn@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ Advance, a minimally invasive consumable glaucoma surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com